The strong 93% market-implied probability against a hantavirus vaccine by the end of 2026 reflects that leading candidates, including DNA and mRNA platforms targeting Andes and other strains, remain largely in preclinical stages or early Phase 1/2 trials as of mid-2026, with no candidate positioned for the multi-year regulatory process needed for FDA or equivalent approval. Recent outbreaks, such as the 2026 Andes virus cases linked to the MV Hondius cruise ship, have heightened awareness but have not triggered accelerated funding comparable to Operation Warp Speed. Limited commercial incentive for rare rodent-borne pathogens, combined with requirements for neutralizing antibodies and multi-dose regimens in trials, sustains the consensus. Realistic shifts would require unexpected large-scale investment or rapid Phase 3 success, neither of which current surveillance data or development timelines indicate.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于Hantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
$116,017 交易量
$116,017 交易量
2026-12-31
$116,017 交易量
$116,017 交易量
2026-12-31
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.The strong 93% market-implied probability against a hantavirus vaccine by the end of 2026 reflects that leading candidates, including DNA and mRNA platforms targeting Andes and other strains, remain largely in preclinical stages or early Phase 1/2 trials as of mid-2026, with no candidate positioned for the multi-year regulatory process needed for FDA or equivalent approval. Recent outbreaks, such as the 2026 Andes virus cases linked to the MV Hondius cruise ship, have heightened awareness but have not triggered accelerated funding comparable to Operation Warp Speed. Limited commercial incentive for rare rodent-borne pathogens, combined with requirements for neutralizing antibodies and multi-dose regimens in trials, sustains the consensus. Realistic shifts would require unexpected large-scale investment or rapid Phase 3 success, neither of which current surveillance data or development timelines indicate.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
市场开放时间： May 4, 2026, 10:39 AM ET
交易量
$116,017结束日期
2026-12-31市场开放时间
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.The strong 93% market-implied probability against a hantavirus vaccine by the end of 2026 reflects that leading candidates, including DNA and mRNA platforms targeting Andes and other strains, remain largely in preclinical stages or early Phase 1/2 trials as of mid-2026, with no candidate positioned for the multi-year regulatory process needed for FDA or equivalent approval. Recent outbreaks, such as the 2026 Andes virus cases linked to the MV Hondius cruise ship, have heightened awareness but have not triggered accelerated funding comparable to Operation Warp Speed. Limited commercial incentive for rare rodent-borne pathogens, combined with requirements for neutralizing antibodies and multi-dose regimens in trials, sustains the consensus. Realistic shifts would require unexpected large-scale investment or rapid Phase 3 success, neither of which current surveillance data or development timelines indicate.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
交易量
$116,017结束日期
2026-12-31市场开放时间
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...The strong 93% market-implied probability against a hantavirus vaccine by the end of 2026 reflects that leading candidates, including DNA and mRNA platforms targeting Andes and other strains, remain largely in preclinical stages or early Phase 1/2 trials as of mid-2026, with no candidate positioned for the multi-year regulatory process needed for FDA or equivalent approval. Recent outbreaks, such as the 2026 Andes virus cases linked to the MV Hondius cruise ship, have heightened awareness but have not triggered accelerated funding comparable to Operation Warp Speed. Limited commercial incentive for rare rodent-borne pathogens, combined with requirements for neutralizing antibodies and multi-dose regimens in trials, sustains the consensus. Realistic shifts would require unexpected large-scale investment or rapid Phase 3 success, neither of which current surveillance data or development timelines indicate.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于
警惕外部链接哦。
警惕外部链接哦。
常见问题